The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Eur Rev Med Pharmacol Sci. 2012 May;16(5):575-81.
Eur Rev Med Pharmacol Sci. 2012.
PMID: 22774396
Clinical Trial.